Keeping it Real: Patient Engagement in Evidence Generation
Regulatory bodies including FDA and EMA are recognizing the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting. Join us to explore the value of patient engagement in the design, delivery, analysis and communication of these RWE studies!
Explore how AI can revolutionize your daily practice in Medical Affairs. This session will present a Regulatory bodies such as the Food and Drug Administration (FDA) and European Medicines Agency (EMA) are increasingly recognising the value of supplementing clinical trial data with real-world evidence to improve understanding of drug performance in the healthcare setting.
Consequently, Pharma companies are increasingly including real-world studies in their evidence
- Understand the opportunities and best practices for involving patient partners in the generation of real-world evidence
- Explore, using case studies, the value of patient engagement in the design, delivery, analysis and communication of real-world studies
- Highlight the importance of Medical Affairs and Health Economics and Outcomes Research (HEOR) professionals in partnering with colleagues from different functions in Pharma to ensure patients are effectively engaged throughout the product lifecycle
- Discuss barriers and propose solutions to optimal patient engagement in real-world studies
Moderator:
Cerise James
Regional Medical Director
Evidence Generation Domain Lead
Panelist:
Dawn Lobban
Co-Founder
Amica Scientific
Panelist:
Susan Thornton
CEO
Cutaneous Lymphoma Foundation
Panelist:
Angela Williams
VP Global HEOR Head
Kyowa Kirin
Panelist:
Bhavik Pandya
Director, Oncology Health Economics
Astellas
